Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells

Chao Dong1,2, Runxiang Yang2, Hongjian Li3,4

  • 1Biomedical Engineering Research Center, Kunming Medical University, Kunming, Yunnan, China.

Scientific Reports
|December 23, 2017
PubMed

Insights

Econazole, an antifungal drug, shows potential as a new PI3K inhibitor for lung cancer treatment. It effectively reduced cancer cell viability and tumor growth, both alone and with cisplatin.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • The phosphatidylinositol-3-kinase (PI3K)/AKT pathway is crucial for lung cancer cell proliferation and survival.
  • Targeting PI3K offers a promising therapeutic strategy for lung cancer.

Purpose of the Study:

  • To identify novel PI3K inhibitors from FDA-approved small molecules.
  • To evaluate the efficacy of econazole as a PI3K inhibitor in non-small cell lung cancer (NSCLC).

Main Methods:

  • Utilized free and open-source protein-ligand docking software for screening.
  • Screened 3167 FDA-approved small molecules for PI3Kα inhibitory activity.
  • Assessed econazole's effects on NSCLC cell lines (H661, A549) and in vivo tumor models.

Main Results:

  • Econazole nitrate demonstrated significant activity in reducing NSCLC cell viability.
  • Econazole decreased p-AKT and Bcl-2 protein levels, promoting apoptosis and inhibiting cell growth.
  • Combination therapy with cisplatin showed additive/synergistic effects; econazole suppressed tumor growth in mice.

Conclusions:

  • Econazole functions as a novel PI3K inhibitor with anti-lung cancer properties.
  • Econazole presents potential as a therapeutic agent for lung cancer, either as a monotherapy or in combination with cisplatin.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K